Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,357
Total Claims
$6.2M
Drug Cost
943
Beneficiaries
$6,558
Cost/Patient
Risk Score Breakdown 7/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+67%
Cost per patient vs peers
$6,558 vs $3,933 avg
-8%
Brand preference vs peers
47.3% vs 51.2% avg
Brand vs Generic
Brand: 8,012 claims · $5.3M
Generic: 8,931 claims · $832K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 926 | $1.0M |
| Empagliflozin | 1,002 | $703K |
| Metformin Hcl | 99 | $587K |
| Dapagliflozin Propanediol | 771 | $521K |
| Insulin Aspart | 620 | $450K |
| Semaglutide | 304 | $329K |
| Insulin Glargine,hum.Rec.Anlog | 513 | $297K |
| Semaglutide | 255 | $275K |
| Insulin Glargine,hum.Rec.Anlog | 583 | $234K |
| Sitagliptin Phosphate | 307 | $214K |
| Linagliptin | 256 | $174K |
| Sitagliptin Phos/Metformin Hcl | 254 | $169K |
| Icosapent Ethyl | 258 | $112K |
| Insulin Lispro | 129 | $83K |
| Insulin Degludec | 135 | $76K |
Prescribing Profile
Patient Profile
73
Avg Age
61%
Female
1.80
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data